On this page
- What multiple sclerosis is
- What standard treatment offers now
- The two procedures, kept separate
- What the aHSCT evidence shows
- What the MSC evidence shows
- What remains unestablished
- Who might reasonably be assessed
- Risks specific to this condition
- Questions that settle which you are being offered
- Frequently asked questions
- Requesting a medical evaluation
More misleading marketing attaches to this condition than to any other in regenerative medicine, and the reason is a single word doing two jobs. Multiple sclerosis and stem cell therapy involves two entirely different procedures with two separate evidence bases, and knowing which one you are being offered is the most useful thing on this page.
What multiple sclerosis is
The immune system attacks the myelin sheath insulating nerve fibres in the brain and spinal cord. Signals slow or fail, and the symptoms depend entirely on where the damage falls.
Most people are diagnosed with a relapsing-remitting pattern — attacks followed by partial or complete recovery. Many later move to a progressive course, where disability accumulates without distinct relapses.
That distinction governs everything about treatment, including which stem cell evidence could conceivably apply.
What standard treatment offers now
Disease-modifying therapies have changed this condition substantially over two decades. The newer high-efficacy agents reduce relapse rates and MRI activity considerably in relapsing disease.
They work best on inflammation, which is why they help relapsing disease far more than progressive disease. Rehabilitation, symptom management and physiotherapy carry much of the rest.
Anyone discussing cell therapy should be doing so alongside this, not instead of it. A clinic that has not asked which disease-modifying therapies you have tried is not assessing you.
The two procedures, kept separate
aHSCT — autologous haematopoietic stem cell transplantation. Chemotherapy suppresses or destroys the misbehaving immune system; your own blood-forming stem cells then rebuild it. Inpatient, haematology-led, with real mortality risk.
MSC therapy — mesenchymal stromal cells, given without conditioning chemotherapy, usually as an outpatient. No immune reset. A different proposed mechanism entirely.
Clinics offer the second. The evidence most often quoted belongs to the first — see HSCT versus MSC infusion.
What the aHSCT evidence shows
It is genuinely strong for a specific population, and it is worth describing accurately rather than borrowing.
A randomised trial compared non-myeloablative aHSCT with continued disease-modifying therapy in relapsing-remitting disease — Effect of Nonmyeloablative Hematopoietic Stem Cell Transplantation vs Continued Disease-Modifying Therapy on Disease Progression.
A meta-analysis has pooled the aHSCT literature — Autologous hematopoietic stem cell transplantation in multiple sclerosis: a meta-analysis — with phase II data — Autologous hematopoietic stem cell transplantation in multiple sclerosis: a phase II trial — and further safety and efficacy analysis — Efficacy and safety of autologous hematopoietic stem-cell transplantation in multiple sclerosis and Effect of autologous hematopoietic stem cell transplantation on multiple sclerosis.
The patients who benefit are typically younger, with aggressive relapsing disease and active inflammation on MRI. It works least well in the progressive disease that most people seeking treatment abroad actually have.
What the MSC evidence shows
Separate, more recent, and at an earlier stage — but real, and improving.
A randomised double-blind trial examined intrathecal MSCs in progressive MS — Intrathecal Mesenchymal Stem Cells in Progressive Multiple Sclerosis: A Randomized, Double-Blind Trial — and related work assessed MSC-neural progenitor therapy — Efficacy of intrathecal mesenchymal stem cell-neural progenitor therapy in progressive MS.
Other studies have looked at neurophysiological outcomes — Neurophysiological outcomes following mesenchymal stem cell therapy in multiple sclerosis — at cerebrospinal fluid biomarkers — Effects of Mesenchymal Stem Cell Transplantation on Cerebrospinal Fluid Biomarkers — at active progressive disease — Beneficial effects of autologous mesenchymal stem cell transplantation in active progressive MS — and at serum markers alongside cognition — Kinetics of serum NFL and GFAP and changes in cognitive functions.
Note the route. Most of this delivers cells into the spinal fluid, not into a vein. An intravenous infusion is a third thing again, and the least supported of the three.
What remains unestablished
That MSC therapy changes the long-term course of MS. The trials above measure biomarkers, neurophysiology and short-interval clinical scores, not disability decades later.
That intravenous MSC infusion — the commonest commercial offer — does anything in MS at all. It is the least studied route.
That any of this repairs existing damage. Remyelination in humans remains a research goal rather than a demonstrated outcome.
Who might reasonably be assessed
For aHSCT: younger patients with aggressive relapsing disease and active inflammation, who have failed disease-modifying therapy, assessed at a specialist centre with haematology and neurology together.
For MSC trials: participation in a registered clinical trial is a more defensible route than a commercial infusion, and costs less.
Progressive disease without inflammatory activity is where the evidence is weakest and where most commercial interest is directed. That mismatch is worth sitting with.
Risks specific to this condition
aHSCT carries infection risk during the period of immune suppression, infertility, and a mortality risk that is small but not zero. It is a serious procedure with serious trade-offs.
MSC infusion carries the general risks described under adverse events, plus the specific risks of intrathecal administration where that route is used.
The largest risk for many people is the one that is not clinical: spending savings and delaying effective disease-modifying therapy on the strength of evidence for a different procedure.
Questions that settle which you are being offered
Ask these before anything else.
- Haematopoietic or mesenchymal cells?
- Is there conditioning chemotherapy? If not, this is not the aHSCT procedure.
- Intravenous, intrathecal or something else?
- Which published trial used that cell type, by that route, in my type of MS?
- Inpatient hospital, or outpatient clinic?
See MSC therapy and the research library for the underlying evidence.
The autoimmune overview covers the wider group, and cognitive decline covers the cognitive endpoints that MS trials have measured.
Frequently asked questions
Will any of this get rid of my MS?
No procedure has been shown to do that. aHSCT can halt inflammatory activity in selected patients; it does not undo damage already done.
Which procedure has the strong evidence?
aHSCT, in younger patients with aggressive relapsing disease. That is an inpatient hospital procedure with chemotherapy, not a clinic infusion.
Does MSC therapy work for MS?
There are randomised trials, mostly delivering cells intrathecally in progressive disease. The evidence is early and the effects measured are largely biomarkers and short-interval scores.
What about an intravenous infusion?
That is the commonest commercial offer and the least studied route in MS. Ask specifically which trial supports it.
I have progressive MS — is this for me?
Progressive disease without inflammatory activity is where evidence is weakest, and where most commercial marketing is aimed. The mismatch is worth taking seriously.
Should I stop my disease-modifying therapy?
Not on the basis of anything read online. Those drugs have substantial evidence behind them and stopping is a decision for your neurologist.
Requesting a medical evaluation
Nothing on this page establishes whether any treatment is appropriate for you. That needs your history, your imaging and your current medications read by a clinician. If you would like that review, send your records and we will tell you honestly whether there is anything worth discussing — including when the answer is no.
This page is general information, not medical advice, and does not create a doctor–patient relationship. Regenerative treatments discussed here are in most cases investigational. Discuss any treatment with a clinician who knows your history.